Every year at about this time (since the late 1990s), Harris Interactive conducts a poll in which they ask consumers whether they think specific industries are doing a good job (or not). The results of the 2008 poll were just published.
Filed under: Business strategy, Health and drug costs | Tagged: reputation industry consumer Harris attitudes | Comments Off
An insightful article by Robert Goldberg of the Centers for Medicine in the Public Interest, entitled “The future of drug development,” appeared today on the FiercePharma web site.
Filed under: Business strategy, Drug approvals and regulation, Drug development / clinical trials | Tagged: FDA, future, innovation, NME | Comments Off
Yesterday the UK’s National Institute for Health and Clinical Excellence (NICE) concluded that £35,000 a year (about US$70,000) for new drugs that have been proven to have efficacy in the management of advanced renal cell carcinoma (kidney cancer) is more than the National Health Service (NHS) can afford.
Filed under: Business strategy, Drug approvals and regulation, Health and drug costs, health economics | Tagged: Add new tag, cancer, cost, economics, kidney, NICE | Comments Off
